Hemostasis and Thrombosis Research

Clinical Research

  • Hemophilia
    • Secondary prophylaxis in severe hemophilia A
    • Risk factors due to low bone density in hemophilia patients
    • fVIII inhibitors in patients with hemophilia undergoing surgery
    • Mechanisms of fVIII inhibitor development
    • Efficacy and safety of novel recombinant products for the treatment of hemophilia
    • Pharmacokinetics and safety of human recombinant fIX
    • 32P synovectomy
    • Evaluation of platelet function of hemophilia
  • Rare Bleeding Disorders
    • Efficacy and safety of recombinant fXIII
  • Platelet Dysfunction
    • Platelet dysfunction of immune and non-immune thrombocytopenia
  • ITP
    • Mechanisms of immune thrombocytopenia
  • Thrombosis
    • Identification of risk factors for the development of thrombosis
    • Establishment of novel recombinant products for the treatment of thrombosis

Clinical and Translational Researchers

Basic and Translational Research

  • Mechanisms of fVIII inhibitor formation and pathogenicity
  • Regulation of fVIII expression
  • Development of novel factor VIII products
  • Mechanisms of platelet activation and thrombosis

Basic Researchers

Recent Publications

  • Dunn AL., Cox Gill J. “Adenotonsillectomy in Patients with Desmopressin Responsive Mild Bleeding Disorders: A Review of the Literature”  Haemophilia 2010;16:711-716.
  • Dunn AL. “Malignancy in Patients with Hemophilia:  A Review of the Literature” Haemophilia 2010;16:427-436.
  • Ide  LM, Iwakoshi  N, Bangadharan  B, Jobe, S, Moot, R, McCarty D, Doering CB,  and Spencer HT. “Functional aspects of factor VIII high expression after nonmyeloablative transplant of gene-modified hematopoietic stem cells for hemophilia A”.  J Gene Med. 2010;12:333-44.
  • Kempton CL, Meeks SL, Harvey DR, and Abshire TC. Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII. Haemophilia. 2011;17:155-6.
  • Kempton CL, Soucie JM, Miller CH, Hooper C, Escobar MA, Cohen AJ, Key NS, Thompson AR,  Abshire TC. In non-severe hemophilia A the risk of inhibitor following intensive factor treatment is greater in older patients: a case-control study.  J Thromb Haemost. 2010; 8:2224-31.
  • McDowall A, Svensson L, Stanley P, Patzak I, Chakravarty P, Howarth K, Sabnis H, Briones M, Hogg N.  Two mutations in the KINDLIN3 gene of a new leukocyte adhesion deficiency III patient reveal distinct effects on leukocyte function in vitro.  Blood 2010;115:4834 - 4842.
  • Patel, SR, Hendrickson, JE, Smith, NH, Cadwell, CM, Ozato, K, Morse, HC, Yoshimi, R, Zimring, JC.  Alloimmunization against RBC or PLT antigens is independent of TRIM21 expression in a murine model.  Molecular Immunology 2010: doi:10.1016/j.molimm.2010.12.017 | epub ahead of print.
  • Sabnis H, Kirpalani A, Horan J, McDowell A, Svensson L, Cooley A, Merck T, Jobe S, Hogg N, Briones M.  Leukocyte adhesion deficiency-III in an African-American patient.  Pediatr Blood Cancer.  2010;55:180-2.
  • Spencer, H.T., Denning, G., Gautney, R., Dropulic. B., Roy, A.J., Baranyi, L., Gangadharan, B., Parker, E.T., Lollar, P., Doering, C.B.,  Lentiviral Vector Platform for Production of    Bioengineered Recombinant Coagulation Factor VIII. Molecular Therapy Epub 2010 Nov 16. [ePub ahead of print).   PMID: 21081907 [PubMed - in process]
  • Summers, R.J., Meeks, S.L., Healey, J.F., Brown, H.C., Parker, E.T., Kempton, C.L., Doering, C.B., and Lollar, P.  Factor VIII A3 Domain Substitution N1922S Results in Hemophilia A Due to Domain-Specific Misfolding and Hyposecretion of Functional Protein. Blood Dec. 16 (ePub ahead of print) DOI 10.1182/blood-2010-09-307074.

Research Collaborations

Clinical and Research Support